<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696423</url>
  </required_header>
  <id_info>
    <org_study_id>111535</org_study_id>
    <nct_id>NCT00696423</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children</brief_title>
  <official_title>Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This protocol posting deals with objectives &amp; outcome measures of the booster phase. The
      objectives &amp; outcome measures of the primary phase are presented in a separate protocol
      posting (NCT number = NCT00412854). This Phase IIIB study will compare GSK Biologicals'
      DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese children 18 to
      24 months of age, in terms of safety and immunogenicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in microgram per milliliter (μg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-diphtheria Toxoid Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in international Unit per milliliter (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tetanus Toxoid Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diphtheria Toxoid Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tetanus Toxoid Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <description>Geometric mean concentrations are given in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</measure>
    <time_frame>Before booster vaccination</time_frame>
    <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>During the 4-day follow-up period after booster vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">467</enrollment>
  <condition>Acellular Pertussis</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Infanrix/Hib Single Injection Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix + Hiberix Separate Injection Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix™</intervention_name>
    <description>Intramuscular injection, one dose</description>
    <arm_group_label>Infanrix/Hib Single Injection Group</arm_group_label>
    <arm_group_label>Infanrix + Hiberix Separate Injection Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hiberix™</intervention_name>
    <description>Intramuscular injection, one dose</description>
    <arm_group_label>Infanrix/Hib Single Injection Group</arm_group_label>
    <arm_group_label>Infanrix + Hiberix Separate Injection Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  Subjects should have completed the full three-dose primary vaccination course in study
             104567.

          -  A male or female child between, and including, 18 and 24 months of age at the time of
             the booster vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding booster vaccination, or planned use during
             the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the booster dose.

          -  Administration of a vaccine not foreseen by the study protocol within 30 days prior to
             vaccination, or planned administration during the study period, with the exception of
             measles or combined measles, mumps and rubella (MMR) vaccination.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Previous booster vaccination against diphtheria, tetanus, pertussis and/or Haemophilus
             influenzae type b diseases since the end of the primary study.

          -  History of diphtheria, tetanus, pertussis and/or Haemophilus influenzae type b
             diseases.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  Major congenital defects or serious chronic illness.

          -  History of any progressive neurological disorders or seizures.

          -  Acute disease and/or fever at time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the booster dose or planned administration during the study period.

          -  Occurrence of any of the following adverse events (AEs) after previous administration
             of a diphtheria-tetanus-pertussis (DTP) vaccine:

               -  Hypersensitivity reaction due to any component of the vaccine.

               -  Encephalopathy.

               -  Fever ≥ 40.0 °C (axillary temperature) within 48 hours of vaccination.

               -  Collapse or shock-like state within 48 hours of vaccination.

               -  Persistent, inconsolable crying occurring within 48 hours of vaccination and
                  lasting ≥ 3 hours.

               -  Seizures with or without fever occurring within 3 days of vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liucheng County</city>
        <state>Guangxi</state>
        <zip>545200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mengshan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <results_first_submitted>July 17, 2009</results_first_submitted>
  <results_first_submitted_qc>July 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2009</results_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infanrix/Hib</keyword>
  <keyword>Chinese children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111535</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infanrix/Hib Single Injection Group</title>
          <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
        </group>
        <group group_id="P2">
          <title>Infanrix + Hiberix Separate Injection Group</title>
          <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infanrix/Hib Single Injection Group</title>
          <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
        </group>
        <group group_id="B2">
          <title>Infanrix + Hiberix Separate Injection Group</title>
          <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="467"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.2" spread="0.79"/>
                    <measurement group_id="B2" value="19.2" spread="0.75"/>
                    <measurement group_id="B3" value="19.2" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in microgram per milliliter (μg/mL).</description>
        <time_frame>One month after booster vaccination</time_frame>
        <population>Analysis was performed on the According To Protocol (ATP) cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in microgram per milliliter (μg/mL).</description>
          <population>Analysis was performed on the According To Protocol (ATP) cohort for immunogenicity.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.428" lower_limit="29.452" upper_limit="40.244"/>
                    <measurement group_id="O2" value="132.075" lower_limit="112.563" upper_limit="154.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in international Unit per milliliter (IU/mL).</description>
        <time_frame>One month after booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in international Unit per milliliter (IU/mL).</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.945" lower_limit="0.905" upper_limit="0.987"/>
                    <measurement group_id="O2" value="0.926" lower_limit="0.887" upper_limit="0.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-tetanus Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in IU/mL.</description>
        <time_frame>One month after booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-tetanus Toxoid Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in IU/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.455" lower_limit="6.881" upper_limit="8.077"/>
                    <measurement group_id="O2" value="10.104" lower_limit="9.080" upper_limit="11.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
        <time_frame>One month after booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="48.1" upper_limit="56.7"/>
                    <measurement group_id="O2" value="55.8" lower_limit="51.7" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="82.6" upper_limit="105.4"/>
                    <measurement group_id="O2" value="92.8" lower_limit="83.3" upper_limit="103.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.9" lower_limit="208.7" upper_limit="266.5"/>
                    <measurement group_id="O2" value="241.6" lower_limit="213.6" upper_limit="273.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
        <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
        <time_frame>One month after booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
          <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotection against PRP (n=238, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection against diphtheria (n=237, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection against tetanus (n=237, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositivity for anti-PT (n=239, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositivity for anti-FHA (n=239, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositivity for anti-PRN (n=239, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRP Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in μg/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PRP Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in μg/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.240" lower_limit="1.085" upper_limit="1.418"/>
                    <measurement group_id="O2" value="2.461" lower_limit="2.136" upper_limit="2.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in IU/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in IU/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" lower_limit="0.053" upper_limit="0.058"/>
                    <measurement group_id="O2" value="0.054" lower_limit="0.052" upper_limit="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-tetanus Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in IU/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-tetanus Toxoid Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in IU/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.219" lower_limit="0.195" upper_limit="0.247"/>
                    <measurement group_id="O2" value="0.311" lower_limit="0.274" upper_limit="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in EL.U/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
          <description>Geometric mean concentrations are given in EL.U/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="10.0" upper_limit="10.2"/>
                    <measurement group_id="O2" value="10.3" lower_limit="9.9" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="10.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="10.3" lower_limit="10.0" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
        <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
          <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
          <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotection against PRP (n= 237, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection against diphtheria (n= 237, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection against tetanus (n= 237, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositivity for anti-PT (n= 239, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositivity for anti-FHA (n= 239, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositivity for anti-PRN (n= 239, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
        <time_frame>During the 4-day follow-up period after booster vaccination</time_frame>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with a documented dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
          <population>Analysis was performed on subjects from the Total Vaccinated Cohort with a documented dose.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
          <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Infanrix/Hib Single Injection Group</title>
          <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
        </group>
        <group group_id="E2">
          <title>Infanrix + Hiberix Separate Injection Group</title>
          <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73"/>
                <counts group_id="E2" subjects_affected="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at injection site</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

